Abstract
In the last 12 years, data has accumulated supporting an important role for hyperglycemia in the development of diabetic nephropathy, and in the same period identification and characterization of renal glucose transporters has expanded rapidly. This new knowledge concerning glucose transporters is now being used to determine the roles they may play in diabetic kidney disease. Recent studies of renal glucose transporters have characterized their responses to diabetes, and their potential roles in the diabetic kidney. Glucose transporters have been shown to be rate-limiting for mesangial cell glucose uptake, glucose metabolism and extracellular matrix (ECM) production by these cells. Furthermore, increased renal GLUT1 has been proposed to play an important role in the development of diabetic glomerulosclerosis. Recent data suggest increased GLUT8 in podocytes may contribute to diabetic glomerular disease as well. Renal tubular glucose transporter expression is also altered in diabetes, responding to the increased need for glucose reabsorption . However, further investigation is required to determine the potential roles of these glucose transporters in the interstitial kidney disease associated with diabetes.
Keywords: Glucose transporter, GLUT, SGLT, diabetic nephropathy, mesangial cell
Current Enzyme Inhibition
Title: Glucose Transporters in Normal and Diabetic Kidneys
Volume: 2 Issue: 3
Author(s): Charles W. Heilig and Youli Wang
Affiliation:
Keywords: Glucose transporter, GLUT, SGLT, diabetic nephropathy, mesangial cell
Abstract: In the last 12 years, data has accumulated supporting an important role for hyperglycemia in the development of diabetic nephropathy, and in the same period identification and characterization of renal glucose transporters has expanded rapidly. This new knowledge concerning glucose transporters is now being used to determine the roles they may play in diabetic kidney disease. Recent studies of renal glucose transporters have characterized their responses to diabetes, and their potential roles in the diabetic kidney. Glucose transporters have been shown to be rate-limiting for mesangial cell glucose uptake, glucose metabolism and extracellular matrix (ECM) production by these cells. Furthermore, increased renal GLUT1 has been proposed to play an important role in the development of diabetic glomerulosclerosis. Recent data suggest increased GLUT8 in podocytes may contribute to diabetic glomerular disease as well. Renal tubular glucose transporter expression is also altered in diabetes, responding to the increased need for glucose reabsorption . However, further investigation is required to determine the potential roles of these glucose transporters in the interstitial kidney disease associated with diabetes.
Export Options
About this article
Cite this article as:
Heilig W. Charles and Wang Youli, Glucose Transporters in Normal and Diabetic Kidneys, Current Enzyme Inhibition 2006; 2 (3) . https://dx.doi.org/10.2174/157340806777934757
DOI https://dx.doi.org/10.2174/157340806777934757 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Anti-Tumor Mechanism and Target of Triptolide Based on Network Pharmacology and Molecular Docking
Recent Patents on Anti-Cancer Drug Discovery An Update on “Selenium Containing Compounds from Poison to Drug Candidates: A Review on the GPx-like Activity”
Current Chemical Biology Medicinal Plants and Bioactive Compounds for Diabetes Management: Important Advances in Drug Discovery
Current Pharmaceutical Design Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Novel Sample Preparation for Mass Spectral Analysis of Complex Biological Samples
Current Proteomics Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Transfection of TGF-β shRNA by Using Ultrasound-targeted Microbubble Destruction to Inhibit the Early Adhesion Repair of Rats Wounded Achilles Tendon In vitro and In vivo
Current Gene Therapy Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Low Osteopontin N-Terminal Fragment and Carotid Plaque Stability Associated with Statin or Antiplatelet Therapy
Current Vascular Pharmacology Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes
Current Medicinal Chemistry Adipokines and Myokines: A Pivotal Role in Metabolic and Cardiovascular Disorders
Current Medicinal Chemistry Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Stem Cell-Based Therapies and Immunomodulatory Approaches in Newly Diagnosed Type 1 Diabetes
Current Stem Cell Research & Therapy Unique Coronary Artery Disease Differences in Women as Related to Revascularization
Current Medicinal Chemistry Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology From Polypharmacology to Target Specificity: The Case of PARP Inhibitors
Current Topics in Medicinal Chemistry Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design